Patents Assigned to HIGHFIELD BIOPHARMACEUTICAL CORPORATION
  • Publication number: 20220031618
    Abstract: An irinotecan liposome preparation, a preparation method, and use thereof. The irinotecan liposome includes: irinotecan, a liposome carrier, an internal aqueous phase located inside a liposome membrane and an external aqueous phase located outside the liposome membrane, the irinotecan being encapsulated in the internal aqueous phase; a sulfonate gradient exists between the internal aqueous phases inside the liposome membrane and the external aqueous phase outside the liposome membrane. The liposome takes monovalent sulfonate and disulfonate as the internal aqueous phases, encapsulates the irinotecan in the internal aqueous phases of the liposome in the form of insoluble sulfonate or disulfonate, and has a good sustained-release effect.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 3, 2022
    Applicant: HighField BioPharmaceutical Corporation
    Inventors: Xiaohui WEI, Bingqi JIANG
  • Patent number: 10952984
    Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 23, 2021
    Assignee: HIGHFIELD BIOPHARMACEUTICAL CORPORATION
    Inventors: Yuhong Xu, Xiaolong Chen, Anjie Zheng, Lieyi Wu
  • Publication number: 20190282530
    Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.
    Type: Application
    Filed: August 17, 2017
    Publication date: September 19, 2019
    Applicant: HIGHFIELD BIOPHARMACEUTICAL CORPORATION
    Inventors: YUHONG XU, XIAOLONG CHEN, ANJIE ZHENG, LIEYI WU